Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis

To evaluate the performance of the extended modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) incorporating information from anteroposterior (AP) lumbar radiographs as compared to the conventional mSA...
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research

Related Links:

The aim of this study was to compare radiographic progression in patients with ankylosing spondylitis (AS) treated for up to 2  years with secukinumab (MEASURE 1) with a historical cohort of biologic-naïve pati...
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to educate the reader about the evolving classification of axial spondyloarthritis (AxSpA) and describe recent treatment data from clinical trials of medications with mechanisms of action other than TNF inhibition. The review will also address emerging treatment strategies for AxSpA.Recent FindingsNew and more sensitive classification schema for AxSpA find that the prevalence of the disease is more than twice that of the historic definition of ankylosing spondylitis (AS), when patients without radiographically observable damage to the sacroiliac joints are included. TN...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
Purpose of review Treat-to-target (T2T) is an emerging management strategy in axial spondyloarthritis (axSpA). The concept was originally based on evidence from other chronic conditions, such as hypertension, diabetes and hypothyroidism, as well as some rheumatic diseases, such as rheumatoid arthritis and gout. The purpose of this review is to discuss the arguments against and in favour of adopting a T2T strategy in the management of axSpA. Recent findings International groups have recommended a T2T strategy in axSpA. Inactive disease according to the Ankylosing Spondylitis Disease Activity Score (ASDAS) has been sugg...
Source: Current Opinion in Rheumatology - Category: Rheumatology Tags: SPONDYLOARTHROPATHIES: Edited by Atul A. Deodhar Source Type: research
Conditions:   Rheumatoid Arthritis;   Psoriatic Arthritis;   Ankylosing Spondylitis;   Non-Radiographical Axial Spondyloarthritis Interventions:   Drug: Filgotinib;   Drug: Placebo;   Drug: Standard of Care Sponsors:   Galapagos NV;   Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we aimed to investigate whether miR ‐17‐5p, miR‐27a, miR‐29a and miR‐126‐3p can be verified as potential biomarkers of axSpA.MethodsPeripheral blood mononuclear cell (PBMC) miRNA expression was evaluated by quantitative real ‐time polymerase chain reaction among 43 patients with AS, 26 patients with non‐radiographic axSpA (nr‐axSpA) and 39 healthy controls. Detailed clinical histories were recorded and the correlation of miRNAs and clinical features were analyzed.ResultsWhen compared to controls, both patients with AS and nr ‐axSpA had significantly higher expression levels of miR‐17‐...
Source: International Journal of Rheumatic Diseases - Category: Rheumatology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionBoth INSPIRE and Domjan methods correlate well as measures of SLF in PsA and correlate with radiographic damage. Therefore, the simpler INSPIRE method may be used to measure SLF in PsA.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
AbstractBackgroundThe natural history of non ‐radiographic axial spondyloarthritis (nr‐axSpA) is incompletely characterized, and there are concerns that non‐steroidal anti‐inflammatory drugs (NSAIDs) provide inadequate disease control in patients with active disease. C‐axSpAnd (NCT02552212), the longest placebo‐controlled trial in nr‐axSpA to date, investigated effects of certolizumab pegol (CZP), an anti‐TNF therapy, in nr‐axSpA patients with objective signs of inflammation.MethodsIn this ongoing, parallel ‐group, double‐blind study, adults with active disease were recruited from 80 centers in Austra...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Full Length Source Type: research
More News: Ankylosing Spondylitis | Arthritis | Radiography | Rheumatology